Milestone Pharmaceuticals Inc (MIST)

$1.97 +0.01 (0.51%)
Market Cap 162.67M
Revenue (ttm) 0.00
Net Income (ttm) -41.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,353,500
Avg Vol 5,858,356
Day's Range N/A - N/A
Shares Out 85.17M
Stochastic %K 50%
Beta 0.44
Analysts Strong Sell
Price Target $6.60

Company Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collabora...

Industry: Biotechnology
Sector: Healthcare
Phone: 514 336 0444
Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Canada
artynonymous
artynonymous Feb. 4 at 1:12 AM
$MIST Has there been any update regarding submission for afib with rvr labeling?
1 · Reply
Savon13
Savon13 Feb. 3 at 10:43 PM
$MIST is this the Cleveland Browns of stocks? Sure feels like it
1 · Reply
Quasi3
Quasi3 Feb. 3 at 8:21 PM
$MIST 6h TF it appears to be forming a bullish wedge - still there is a chance to move up :)
0 · Reply
Ga_glovo
Ga_glovo Feb. 3 at 7:46 PM
$MIST todays NVO case should be positive for MIST - big pharmas need names like MIST and similar to offset patent cliff
0 · Reply
Diverstj981
Diverstj981 Feb. 3 at 7:25 PM
$MIST Every day we just keep getting jerked off with no happy ending.
0 · Reply
johnnydankworth
johnnydankworth Feb. 3 at 5:38 PM
$MIST Hmm the shareholders need an inducement grant as well...
1 · Reply
audiobookprisonstories
audiobookprisonstories Feb. 3 at 5:07 PM
$SLS $ALT $IBRX $OCGN $MIST i been WITH JACK 2 YEARS AND HE IS AMAZING.
1 · Reply
Quasi3
Quasi3 Feb. 3 at 4:45 PM
$MIST will we finally close firmly above $2 ?;)
1 · Reply
JanetBSmellin
JanetBSmellin Feb. 3 at 4:45 PM
$MIST Anyone else see a 3.68M candle at 9:49a.m.?
2 · Reply
Streax
Streax Feb. 3 at 3:59 PM
$GTBP time for a reversal? FDA news! $SPY $FAT $MIST $OPEN
1 · Reply
Latest News on MIST
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 3, 2026, 8:00 AM EST - 12 hours ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Jan 26, 2026, 8:00 AM EST - 8 days ago

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense

Jan 15, 2026, 9:45 AM EST - 19 days ago

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Jan 6, 2026, 8:00 AM EST - 4 weeks ago

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript

Dec 15, 2025, 11:59 AM EST - 7 weeks ago

Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Dec 12, 2025, 8:00 PM EST - 7 weeks ago

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Nov 12, 2025, 7:01 AM EST - 2 months ago

Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Nov 3, 2025, 8:00 AM EST - 3 months ago

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Oct 9, 2025, 8:00 AM EDT - 4 months ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Aug 19, 2025, 8:00 AM EDT - 6 months ago

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Aug 12, 2025, 7:05 AM EDT - 6 months ago

Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Jul 18, 2025, 2:16 PM EDT - 7 months ago

Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Jul 11, 2025, 2:37 PM EDT - 7 months ago

Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Jul 11, 2025, 9:30 AM EDT - 7 months ago

Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering

Jul 11, 2025, 6:01 AM EDT - 7 months ago

Milestone Pharmaceuticals Announces Proposed Public Offering

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Jul 11, 2025, 6:00 AM EDT - 7 months ago

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Jul 7, 2025, 10:01 AM EDT - 7 months ago

Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Jun 16, 2025, 8:00 AM EDT - 8 months ago

Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 8 months ago

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

May 14, 2025, 7:04 AM EDT - 9 months ago

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Stock Picks From Seeking Alpha's March 2025 New Analysts

Apr 4, 2025, 2:30 PM EDT - 10 months ago

Stock Picks From Seeking Alpha's March 2025 New Analysts

AI ARGX CCL CEPU CF CROX CUK

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

Mar 28, 2025, 10:24 AM EDT - 11 months ago

Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

Mar 28, 2025, 7:06 AM EDT - 11 months ago

US FDA declines to approve Milestone Pharma's heart rhythm nasal spray

FDA Issues Complete Response Letter for Etripamil for PSVT

Mar 28, 2025, 7:00 AM EDT - 11 months ago

FDA Issues Complete Response Letter for Etripamil for PSVT

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Mar 21, 2025, 3:18 PM EDT - 11 months ago

Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Mar 20, 2025, 8:00 AM EDT - 11 months ago

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Mar 13, 2025, 7:08 AM EDT - 11 months ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Feb 19, 2025, 8:00 AM EST - 1 year ago

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Feb 11, 2025, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Jan 28, 2025, 8:00 AM EST - 1 year ago

Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Nov 12, 2024, 9:03 AM EST - 1 year ago

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Aug 8, 2024, 4:17 PM EDT - 1 year ago

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

May 31, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 29, 2024, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

May 13, 2024, 7:15 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Apr 8, 2024, 11:36 AM EDT - 1 year ago

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Mar 21, 2024, 7:14 AM EDT - 2 years ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 4:01 PM EST - 2 years ago

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Feb 29, 2024, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Feb 28, 2024, 4:37 PM EST - 2 years ago

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

Jan 2, 2024, 7:06 AM EST - 2 years ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

CORT RPID

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Dec 26, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 21, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

artynonymous
artynonymous Feb. 4 at 1:12 AM
$MIST Has there been any update regarding submission for afib with rvr labeling?
1 · Reply
Savon13
Savon13 Feb. 3 at 10:43 PM
$MIST is this the Cleveland Browns of stocks? Sure feels like it
1 · Reply
Quasi3
Quasi3 Feb. 3 at 8:21 PM
$MIST 6h TF it appears to be forming a bullish wedge - still there is a chance to move up :)
0 · Reply
Ga_glovo
Ga_glovo Feb. 3 at 7:46 PM
$MIST todays NVO case should be positive for MIST - big pharmas need names like MIST and similar to offset patent cliff
0 · Reply
Diverstj981
Diverstj981 Feb. 3 at 7:25 PM
$MIST Every day we just keep getting jerked off with no happy ending.
0 · Reply
johnnydankworth
johnnydankworth Feb. 3 at 5:38 PM
$MIST Hmm the shareholders need an inducement grant as well...
1 · Reply
audiobookprisonstories
audiobookprisonstories Feb. 3 at 5:07 PM
$SLS $ALT $IBRX $OCGN $MIST i been WITH JACK 2 YEARS AND HE IS AMAZING.
1 · Reply
Quasi3
Quasi3 Feb. 3 at 4:45 PM
$MIST will we finally close firmly above $2 ?;)
1 · Reply
JanetBSmellin
JanetBSmellin Feb. 3 at 4:45 PM
$MIST Anyone else see a 3.68M candle at 9:49a.m.?
2 · Reply
Streax
Streax Feb. 3 at 3:59 PM
$GTBP time for a reversal? FDA news! $SPY $FAT $MIST $OPEN
1 · Reply
Syndr78
Syndr78 Feb. 3 at 3:45 PM
$MIST The issue 419,000 options to two new incoming employees? What are the roles of these new employees? Not sure how quickly they can sell them back into the market as dilution, but I guess more importantly what I want to know are the new employees titles and roles within the company? Ultimately, can this at least theoretically indicate that they are not in any type of buyout discussions for the time being?
1 · Reply
Paragon_73
Paragon_73 Feb. 3 at 3:40 PM
$MIST
1 · Reply
keokeostwiz
keokeostwiz Feb. 3 at 3:25 PM
$MIST Interested purchaser buying everything under 2 today.....laying foundation for eventual buyout....only the waiting remains......GLTA
0 · Reply
Gabriel_DS
Gabriel_DS Feb. 3 at 3:10 PM
$MIST this volume and still flat
0 · Reply
JrNannies
JrNannies Feb. 3 at 2:59 PM
$MIST magic mist lets go
0 · Reply
Ga_glovo
Ga_glovo Feb. 3 at 2:51 PM
$MIST wtf...someone cleared everything for over 3m?
1 · Reply
fookme
fookme Feb. 3 at 2:48 PM
$MIST 3.8M volume!
0 · Reply
Ga_glovo
Ga_glovo Feb. 3 at 2:42 PM
$MIST 2.0 is a magic round number here 🫤
0 · Reply
Diverstj981
Diverstj981 Feb. 3 at 1:56 PM
$MIST A bit of news from investor relations. https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-reports-inducement-grants-under-6
1 · Reply
Enodloca
Enodloca Feb. 3 at 1:45 PM
$MIST
0 · Reply
kellymone2
kellymone2 Feb. 3 at 1:41 PM
$MIST https://investors.milestonepharma.com/news-releases/news-release-details/milestone-pharmaceuticals-reports-inducement-grants-under-6
0 · Reply
jacksparo
jacksparo Feb. 3 at 1:28 PM
$SLS $ALT $IBRX $OCGN $MIST Turned my full surveillance newly installed self created app ( I create most of my A.I tools using special software languages, got 24 years of programming experience used to work in top high tech companies in the past) to monitor: The pre /day/after / overnight volume blocks! To analyze the volume ( buy , sell ) To understand the level of any possible institutional activities! To monitor the level of the liquidation and short interest! To understand the level 2 plus any Capex related to the options contract! Also to see if any news: surprise volume increase and how it’s driven the price up or down! It will also take me auto notes about any chart indicators changes intra day! I rely on long hours of researching to trade any stock. I don’t rely on others to push a stock for me because that’s simply a typical front loading old style no smart trades there and zero skills! If you are a real trader then you have to capitalize on the opportunities either before they arise or during the momentum’s intra day action! I have been here in Stocktwits for almost 10 years saw a lot of those what so called stocks gurus come and go! I stayed and most of them have gone along the way ✅✅!
4 · Reply